key: cord-0961201-egufwhd2
authors: Favas, T. T.; Dev, Priya; Chaurasia, Rameshwar Nath; Chakravarty, Kamlesh; Mishra, Rahul; Joshi, Deepika; Mishra, Vijay Nath; Kumar, Anand; Singh, Varun Kumar; Pandey, Manoj; Pathak, Abhishek
title: Neurological manifestations of COVID-19: a systematic review and meta-analysis of proportions
date: 2020-10-21
journal: Neurol Sci
DOI: 10.1007/s10072-020-04801-y
sha: 196cd742f9af3d60a09d2155f652c7f1aad371ed
doc_id: 961201
cord_uid: egufwhd2

BACKGROUND: Coronaviruses mainly affect the respiratory system; however, there are reports of SARS-CoV and MERS-CoV causing neurological manifestations. We aimed at discussing the various neurological manifestations of SARS-CoV-2 infection and to estimate the prevalence of each of them. METHODS: We searched the following electronic databases; PubMed, MEDLINE, Scopus, EMBASE, Google Scholar, EBSCO, Web of Science, Cochrane Library, WHO database, and ClinicalTrials.gov. Relevant MeSH terms for COVID-19 and neurological manifestations were used. Randomized controlled trials, non-randomized controlled trials, case-control studies, cohort studies, cross-sectional studies, case series, and case reports were included in the study. To estimate the overall proportion of each neurological manifestations, the study employed meta-analysis of proportions using a random-effects model. RESULTS: Pooled prevalence of each neurological manifestations are, smell disturbances (35.8%; 95% CI 21.4–50.2), taste disturbances (38.5%; 95%CI 24.0–53.0), myalgia (19.3%; 95% CI 15.1–23.6), headache (14.7%; 95% CI 10.4–18.9), dizziness (6.1%; 95% CI 3.1–9.2), and syncope (1.8%; 95% CI 0.9–4.6). Pooled prevalence of acute cerebrovascular disease was (2.3%; 95%CI 1.0–3.6), of which majority were ischaemic stroke (2.1%; 95% CI 0.9–3.3), followed by haemorrhagic stroke (0.4%; 95% CI 0.2–0.6), and cerebral venous thrombosis (0.3%; 95% CI 0.1–0.6). CONCLUSIONS: Neurological symptoms are common in SARS-CoV-2 infection, and from the large number of cases reported from all over the world daily, the prevalence of neurological features might increase again. Identifying some neurological manifestations like smell and taste disturbances can be used to screen patients with COVID-19 so that early identification and isolation is possible.

All published randomized controlled trials, non-randomized controlled trials, case-control studies, cohort studies, crosssectional studies, case series, and case reports, if they had sufficient data on neurological features, laboratory parameters, imaging findings were included in this review. Only those studies were included in which subjects were diagnosed with SARS-CoV-2 infection by real-time RT-PCR or high throughput sequencing analysis of swab specimens or serology or culture. We also included pre-prints and letters if they included data on neurological manifestations in COVID-19. Editorials, systematic reviews, meta-analysis, narrative reviews, conference abstracts, commentaries, animal studies, post-mortem studies, and where translation into English was not possible were excluded. The authors were contacted twice by email if any missing data in the articles.

Databases selected were searched independently by two members (TF and AP) in the team, and, following duplicate removal, reviewed all the articles and selected articles based on inclusion and exclusion criteria. Reporting was done according to the recommendations of the PRISMA statement [25] . Quality of the non-randomized studies was evaluated using the Newcastle-Ottawa Scale [26, 27] and the quality of one randomized controlled trial was assessed using the CONSORT criteria [28] . Any disagreements between two main reviewers were discussed with a third evaluator. Data about the author's name, publication date, study setting and design, time and duration of the study, follow-up, the total number of patients evaluated, study population, age, gender, co-morbidities, neurological features, laboratory parameters, imaging findings, morbidity, and mortality were extracted.

Primary outcomes assessed were neurological manifestations in COVID-19 patients and its prevalence. For the categorical variables, simple and relative frequency and proportions were used. For continuous variables, central tendency (mean or median) and dispersion measures (standard error, standard deviation) were used. To measure association, risk ratios, odds ratios, and hazard ratios were used and 95% confidence intervals calculated. We also assessed secondary outcomes like the association of neurological manifestations with age, co-morbidities, lab parameters including CSF study, imaging features, length of hospital stay, ICU admission, time from onset of typical COVID-19 symptoms to neurological manifestations, and morbidity/mortality.

Data synthesis and illustration were done in tables and figures. For the categorical variables, simple and relative frequency and proportions were used. For continuous variables, measures of central tendency (mean or median) and dispersion (standard error, standard deviation) were calculated. The primary aim of our study was to synthesize the findings from multiple studies that investigated the issues related to neurological manifestations in COVID-19 and thus provide a quantitative summary, to better direct future work. The data are available in the form of proportions, defined as the number of cases of interest in a sample with a particular characteristic divided by the size of the sample. To achieve the objective of obtaining a more precise estimate of the overall proportion for a certain event (neurological manifestations) related to COVID-19, the study employed meta-analysis of proportions using a random-effects model and by the DerSimonian-Laird method [29, 30] . We performed data analysis using metapackages in R (version 3.5.0). Heterogeneity was assessed using the I 2 value. I 2 can take values from 0% to 100% and it is assumed that an I 2 of 25%, 50%, and 75% indicate low, medium, and large heterogeneity respectively [31] . Forest plot was used to visualize the point estimates of study effects and their confidence intervals. Publication bias was evaluated using the funnel plot.

Among the 6789 articles identified, 212 studies were included in the systematic review and 74 studies in the meta-analysis (PRISMA flow diagram (Fig. 1) ). Out of them, most were retrospective studies, 18 were cohort studies, 11 were prospective studies, nine were cross-sectional studies, one was a randomized controlled trial, one was a case-control study and the rest were all case series and case reports. Among these studies, we found only 19 studies, which investigated specifically neurological features in COVID-19 patients. Other studies, evaluated parameters in general. Table 1 shows a summary of all the observational studies included.

The overall incidence of smell disturbances in the studies ranged from 4.9-85.6% [49, 54] and the most common type of smell disturbance was anosmia. Other smell disturbances noticed were hyposmia, phantosmia, and parosmia [54] . Similarly, the incidence of taste disturbances reported was 0.3-88.8% [47, 54] and the most commonly reported were dysgeusia and ageusia. In the meta-analysis, we found 17 and 14 studies, which assessed the prevalence of smell and taste disturbances respectively and disturbances of smell (35.8%; 95%CI 21.4-50.2) and taste (38.5%; 95%CI 24.0-53.0) sensation were the most common neurological manifestation followed by non-specific neurological manifestations.

A case-control study of 79 COVID-19 patients and 40 historical controls of influenza patients from Spain [52] revealed that new-onset smell and taste disorders were significantly higher in the COVID-19 group. Patients in COVID-19 were significantly younger. Another study reported olfactory and taste disturbances occur more frequently in females than males [53] . Lechien et al. [54] , Gilani S et al. [140] , and Rachel Kaye et al. [141] reported that anosmia can be the initial and early manifestations of COVID-19. Population surveys on new-onset olfactory dysfunction from Iran [142] and UK [143] have reported an increase in olfactory dysfunction during the COVID-19 pandemic.

The most common non-specific neurological symptoms reported in SARS-CoV-2 infection were myalgia, headache syncope, and dizziness. The overall pooled prevalence estimate of the proportion of cases are given in Table 3 . Incidence of myalgia reported in various studies ranged from 1.8-62.5% [47, 111] , headache from 0.6-70.3% [90, 111] , and dizziness from 0.6-21% [47, 113] . In children, myalgia and dizziness were less common and rarely reported. In health care workers, the incidence of myalgia, headache, and dizziness was higher compared with the general (48) Myalgia-16 (16) Vertigo-4 (4) Headache-6 (6) Medica staff vs non-medical Death-11 (11) Hospitalization-53 (52) Cured-37 (37) Dawei Wang [98] All the discharged (alive at home and dead) patients with confirmed COVID-19 ( population. Syncope was reported in three studies with incidence of 0.3% [45] , 0.6% [49] , and 4.8% [86] . Few studies showed an increase in creatine kinase, LDH, and myoglobin in COVID-19 patients [12, 62, 66] .

Acute cerebrovascular disease (CVD) was reported in 0.5-5.9% [33, 48] of COVID-19 patients. Out of them, the most common type was acute ischaemic stroke and severe COVID-19 patients were more at risk of developing the acute CVD [33] . From these studies, the incidence of acute CVD in severe/ICU patients reported were 0.8-9.8% [33, 41] . The incidence of ischaemic stroke, hemorrhagic stroke, and cerebral venous thrombosis reported from various studies ranged from 0.4-4.9% [33, 48] , 0.2-0.9% [38, 48] , and 0.3-0.5% [33, 47] respectively. A study by Mao et al. [32] reported that two patients presented with hemiplegia without any typical COVID-19 symptoms. The median time to onset of cerebrovascular disease was 9 days. Another study by Li Y et.al [33] showed that acute CVD was more likely to be present with severe COVID-19; however, they were older, and had cardiovascular risk factors. These findings were similar to the above study by Mao et al. [32] . In both these studies, the laboratory parameters in patients with CNS symptoms were different from the other COVID-19 [32, 33] .

We found two studies that specifically studied the thrombotic complications in COVID-19 patients and found acute ischaemic stroke in COVID-19 patients receiving thromboprophylaxis [35, 36] . A retrospective observational case series in COVID-19 patients from Italy [144] reported six cases of stroke, four were ischaemic and two were hemorrhagic. Five of them had pre-existing vascular risk factors. Three patients with ischaemic stroke and one patient with hemorrhagic stroke showed hypercoagulable blood parameters [144] . Two studies reported six cases of stroke in young(< 50 years) COVID-19 patients, out of which three patients did not have any risk factors [145, 146] .

Also there are multiple case reports and case series of ischaemic stroke including large artery [147] , aneurysmal [148, 149] and non-aneurysmal SAH [51] , deep cerebral venous thrombosis [150] [151] [152] [153] [154] [155] [156] [157] , hemorrhagic stroke [38, 158, 159] and CNS vasculitis [160] from all over the world in COVID-19 patients [38, 51, .

Several cases of meningoencephalitis and encephalopathy were reported in COVID-19 patients [39, 43, 49, [174] [175] [176] [177] [178] [179] [180] [181] [182] [183] . The incidence of encephalitis reported in two retrospective studies was 0.03% [43] and 0.1% [49] . Only in four of the 15 reported cases of encephalitis, CSF RT-PCR test was positive for SARS-CoV-2 RNA, and surprisingly two cases among them had negative nasopharyngeal swab [50, [174] [175] [176] . Two reports showed elevated levels of cytokines like IL-6, IL-8, TNF-α, β2-microglobulin, IP-10, MCP-1 in CSF [177, 181] . Interestingly, fluid from the surgical evacuation of subdural hematoma was positive for SARS-CoV-2 RT-PCR in a COVID-19 patient [184] . Isolated meningoencephalitis without any respiratory involvement has also been reported [175, 185] . Another case of rhombencephalitis as a rare complication of COVID-19 patient has been reported [186] . Few retrospective studies [32, 47, 49] reported seizures with the incidence ranging from 0.5-1.4% [32, 47] . Cases of all types of seizures like febrile seizures [42] , focal seizures [180, [187] [188] [189] , generalized tonic-clonic seizures [183, [190] [191] [192] , myoclonic status epilepticus [193] , status epilepticus [188, 194] and non-convulsive status epilepticus [46] were reported in COVID-19 patients. Generally, the SARS-CoV-2 virus causes mild disease in children. However, a study from Italy showed a total five patients with seizures, and out of them, two had febrile seizures (three children had a known history of epilepsy, one child had a history of febrile seizures, one child had a first episode of febrile seizures) [42] . Also, a case of a 6-weekold infant with SARS-CoV-2 in addition to rhinovirus, presenting with brief 10-15-s episodes of upward gaze and bilateral leg stiffening was reported with normal EEG and MRI brain [195] . Another case of an 11-year-old child with COVID-19 viral encephalitis has been reported, with CSF showing viral encephalitis picture [194] .

PRES syndrome has also been reported in studies [47, 51] . Transient cortical blindness like presentation of PRES syndrome with MRI brain at admission revealing bilateral T2/ FLAIR hyperintensities, especially left occipital, frontal cortical white matter and splenium of the corpus callosum and diffusion restriction in DWI revealing vasogenic edema has been reported [196] . Repeat MRI after 2 weeks showed a complete resolution of findings. Cases of acute necrotizing hemorrhagic encephalopathy [191, 197] , hypoxic brain injury with encephalopathy [43, 47, 51, 65] , delayed post-hypoxic l e u k o e n c e p h a l o p a t h y [ 1 9 8 ] , m i l d e n c e p h a l i t i s / encephalopathy with a reversible splenial lesion(MERS) [199] , ADEM in elderly females [200, 201] , MS plaque exacerbation [47] and CIS [176] were reported in SARS-CoV-2 infected patients. Incidence of disturbances of consciousness/delirium ranged from 3.3-19.6% [49, 100] in retrospective studies. S.R. Beach, et al. [202] reported four cases of elderly COVID-19 patients, who presented to the hospital with altered mental status without any respiratory complaints, and only one among them developed respiratory complaints during the hospital stay. Similar cases have been reported in elderly patients from Saudi Arabia [203] , Norway [204] and China [205] . An observational case series from France [39] in 58 COVID-19 patients with ARDS admitted in ICU reported agitation in 40(69%) patients, confusion in 26 of 40 patients, diffuse corticospinal tract signs in 39 patients (67%) and out of the 45 patients discharged, 15(33%) had a dysexecutive syndrome. MRI Brain showed enhancement of leptomeningeal spaces in eight patients, bilateral frontotemporal hypoperfusion in 11 patients who underwent perfusion imaging, two asymptomatic patients with small acute ischaemic stroke and one patient with subacute ischaemic stroke.

There are multiple reports of GBS in patients with confirmed COVID-19. GBS has also been reported to be a presenting feature in one case report by Zhao H et al. [206] where the patient, later on, developed fever and other symptoms of COVID-19. All the variants of GBS like AIDP, AMAN, AMSAN has been reported in COVID-19 patients [47, [206] [207] [208] [209] [210] [211] [212] [213] [214] [215] [216] [217] [218] [219] including both para [206] [207] [208] [209] [210] [211] [212] [220] [221] [222] [223] and postinfectious pattern [210, 211, [214] [215] [216] [217] [218] [219] [224] [225] [226] . Toscano et al. [227] reported a series of five patients of COVID-19 with GBS, with the interval between the onset of fever, cough and symptoms of GBS ranging from 5 to 10 days. Cases of MFS were also reported [47, 226, 228, 229] . One case of MFS was associated with a positive serum GD1b-IgG antibody [228] . Other rare variants reported were GBS/MF overlap syndrome [219] , AMSAN variants with severe autonomic neuropathy [219] , facial diplegia [222, 227] and postinfectious pattern of the demyelinating type of GBS with brainstem and cervical leptomeningeal enhancement [225] . Cranial neuropathies with abnormal perineural or cranial nerve findings [230] , multiple cranial neuropathies [211, 219] , peripheral motor neuropathy [231] and ataxia [32, 43, 51] are all reported as presentations of COVID-19.

The incidence of rhabdomyolysis has been reported between 0.2-2.6% in different studies [11, 49, 139] . A report illustrates a 38 year-old COVID-19 patient presenting with fever, dyspnea, and severe myalgia, with high creatine kinase (>42,670 U/L) and LDH (4301 U/La) and was diagnosed as viral myositis [232] . Another two cases of adult COVID-19 patients with lower extremity pain and weakness with rhabdomyolysis with high creatine kinase and LDH were reported [233, 234] . First case developed rhabdomyolysis on the 9th day of admission [233] and 2nd case presented to the hospital with rhabdomyolysis [234] . An isolated case of postinfectious myelitis has been reported from Germany in a COVID-19 patient [235] .

Three cases of generalized brainstem type of myoclonus were reported from Spain, with normal CSF study in one patient (others not done) and normal imaging findings. However, nasopharyngeal RT-PCR for SARS-CoV-2 was positive in only one patient. In all these patients, EEG was showing mild diffuse slowing without any epileptic activity [236] . Paresthesias [51] and cutaneous hyperaesthesia [237] were reported as a presentation in COVID-19 patients. A case of COVID-19 patient with oropharyngeal dysphagia followed by aspiration pneumonia, taste impairment, impaired pharyngolaryngeal sensation, and nasopharyngeal contractile dysfunction with absent gag reflex was reported from Japan [238] . Visual symptoms were also reported in a few studies. Mao L et al. [32] reported visual impairment in 1.4% of the COVID-19 patients. Cases of optic neuritis [49] , isolated central retinal artery occlusion [239] , non-arteritic type of posterior ischaemic optic neuropathy (PION) [240] Table 4 .

The heterogeneity was high in most of the neurological manifestations studied except for hemorrhagic stroke (medium), cerebral venous thrombosis (low), seizure (low), and ataxia (low). The funnel plots were symmetric in hemorrhagic stroke, ataxia, seizures, cerebral venous thrombosis and myalgia, which is pointing towards no bias in the selection of publications that are included in the study. However, the funnel plots were asymmetric in other neurological manifestations studied, which pointed towards the heterogeneity in the studies undertaken or bias in the selection of publications included in the study.

In this systematic review and meta-analysis, we assessed the neurological manifestations, risk factors, mortality, laboratory parameters, and imaging findings in those patients with neurological features. Involving 30,159 patients, our metaanalysis is the first and most comprehensive study about the neurological manifestations of COVID-19.

The most common neurological manifestations reported were smell and taste disturbances. Another interesting finding is the geographical variations in the frequency of smell and [54] while studies from Asian countries showed a lower incidence [32] . However, most of the studies which reported a higher incidence of smell and taste disturbances evaluated mainly olfactory and taste symptoms only and studied mild to moderate cases and excluded severe/ICU patients compared with studies with lower incidence. This bias might have caused under-reporting of smell and taste disturbances in severe/ICU patients or could also be because of decreased awareness of investigator about these symptoms at the beginning of the pandemic. Supporting our assumption, a study from Spain which evaluated 841 COVID-19 patients with neurological manifestations reported only 4.9% of cases of smell disturbances and 6.2% cases of taste disturbances [49] .

Other possibilities for these variations are, the difference in affinity of SARS-CoV-2 to tissues between populations, a different strain of mutated virus circulating in Europe compared with Asian countries. However, more studies are required to confirm these assumptions. Interestingly a study by Wan Y et al. [241] predicted that binding affinity between 2019-nCoV and human ACE2 may be enhanced by a single N501T mutation. Also, ACE2 receptors are highly expressed by sustentacular cells of the olfactory epithelium. Olfactory and taste disorders were more common in younger patients [52, 140] most occurs in the early stages as initial manifestations of the disease and even as the only manifestation of COVID-19. Hence, olfactory and gustatory disorders can be the initial and early manifestations of COVID-19 and early identification of these symptoms might lead to early diagnosis and disease containment. Non-specific neurological manifestations could be just systemic features of a viral infection. Similar to olfactory disturbances, the incidence of myalgia, headache, and dizziness also shows geographical variations with the highest incidence reported from Europe, the USA, and Chile. The incidence of non-specific symptoms was lower in children. We noticed that non-specific symptoms were higher among the studies conducted in health care workers. This may be due to increased knowledge and awareness of the symptoms and disease.

The most common type of acute CVD reported was an ischaemic stroke. Hemorrhagic stroke, deep cerebral venous thrombosis, SAH (both non-aneurysmal and aneurysmal), and TIA were also reported; however, with much lesser prevalence. Severe infection or ICU requirement, older age, cardiovascular risk factors, prior co-morbidities, and hypercoagulable lab parameters were found to be a risk factor for developing acute CVD [32, 33] . The apparent association of COVID-19 and stroke is likely due to the sharing of similar risk factors. The severity of COVID-19 has been proved to be directly related to the presence of co-morbidities like hypertension and DM. An earlier meta-analysis by Yang J et al. [242] comprising [46, 243] COVID-19 patients reported the prevalence of risk factors, hypertension in 21.1%, DM in 9.7%, and cardiovascular diseases in 8.4%. Also, hypercoagulable blood parameters as shown by Li Y et.al [33] , can lead to ischaemic stroke and cerebral venous thrombosis. Nervous system involvement in SARS-CoV-2 infection can be due to direct invasion of neural tissues, inflammatory response, or immune dysregulation. The SARS-CoV-2 virus uses the ACE2 and TMPRSS2 for entry to the host cell and it is one of the main determinants of infectivity [241, 244] . Susceptibility to infection correlated with ACE2 expression in previous studies [245] .

Very few retrospective studies showed meningoencephalitis as a presentation of COVID-19; however, there are multiple case reports from all over the world. The probable mechanism can again be direct invasion via the hematogenous route or retrograde pathway via peripheral nerve terminals. Two studies even showed higher levels of inflammatory cytokines in the CSF analysis of these patients [177, 181] . SARS-CoV-2 could trigger a seizure in predisposing patients through neurotropic mechanisms as explained earlier [188] . However, more evaluation is required in this field to find a temporal factor. All types of seizures were reported like febrile seizures, focal seizures, generalized tonic-clonic seizures, status epilepticus and myoclonic status epilepticus, NCSE and also brainstem type of myoclonus. Demyelinating disorders like ADEM, exacerbation of MS plaque, and the clinically isolated syndrome were all reported in COVID-19 patients.

Cases of GBS and its variants were also reported in COVID-19. Both post-infectious and pre-infectious pattern of GBS were reported. The most common type of GBS reported was AIDP. Other variants like AMAN, AMSAN, Miller Fisher syndrome, and facial diplegic variant were also reported. Patients presenting as GBS without any other typical symptoms of COVID-19 were also reported. Possible pathogenesis of GBS in COVID-19 includes immune dysregulation secondary to systemic hyper inflammation and cytokines produced as described by McGonagle et al. [246] and Quin et al. [247] . Hence, it is important to suspect and test for COVID-19 in those patients presenting with GBS and MFS. However, more studies are required to conclude that these cases were not just coincidental and COVID-19 itself is a trigger for GBS and MFS. GBS was also reported in other recent important viral infections like MERS-CoV [248] and Zika virus [243] .

Change in laboratory parameters was also reported in COVID-19 patients with neurological manifestations like higher white cell and neutrophil counts, reduced lymphocyte and platelet counts, elevated CRP and D-dimer levels, and higher levels of creatine kinase, LDH, and myoglobin [12, 32, 33, 62] .

High heterogeneity in our study could be because of differences in the selection of patients and ethnicity, the severity of the disease, co-morbidities, only a few studies evaluated neurological symptoms specifically, variation in the number of patients in different studies, or due to publication bias and differences in the methodology among the studies.

Earlier meta-analyses addressing general clinical features in COVID-19 were published. One such study showed myalgia in (28.5%; 95%CI 21.2-36.2), headache (14.0%; 95%CI 9.9-18.6), and dizziness (7.6%; 95%CI 0.0-23.5) [249] . Our results also found similar results for myalgia, headache, and dizziness, i.e. (19.3%; 95%CI 15.1-23.6), (14.7%; 95%CI 10.4-18.9), and (6.1%; 95%CI 3.1-9.2) respectively. Another similar meta-analysis also showed myalgia in (21.9%; 95%CI 17.7-26.4) and headache in (11.3%; 95%CI 8.9-14.0) [250] . One more study reported the prevalence of headache as (8.0%; 95%CI 5.7-10.2) [251] . However, no meta-analyses are published on the specific neurological manifestations till now.

The strength of our study is that we did a comprehensive search in all the electronic databases. Study limitations include high heterogeneity in the estimation of the prevalence of some neurological manifestations, the inclusion of studies with very small sample size, and lack of meta-regression analysis. We excluded studies in languages other than English where translation was not possible. Most of the included studies were of moderate quality. More good-quality prospective cohort studies are required to establish that the neurological manifestations reported in the studies were not just coincidental.

In conclusion, our study showed neurological manifestations are common in COVID-19 and are even present as the only symptom without any other manifestation of the respiratory system involvement. Hence it is important to suspect every COVID-19 patient with neurological manifestations. In this pandemic, a neurologist needs to take necessary precautions while examining the patients presenting to them. Also, some symptoms like smell and taste disturbance can be used as a screening tool for SARS-CoV-2 infection and can help isolate suspected patients earlier to avoid the spread of the disease.

Author contributions TF and AP conceptualized the study and searched and screened the literature. PD and RNC extracted and analysed the data. RNC contributed to figures, tables, and interpretation of images. KC was involved in extraction of data. DJ, VNM, TF, and AP were involved in study design, data interpretation, and data analysis. RM and MP did the statistical analysis. AK drafted the manuscript, data collection, figures. VKS did literature search, drafted the manuscript, and contributed to study design. TF wrote the first draft of the manuscript with input from AP.

Data availability All data available on request.

Conflict of interest The authors declare that they have no competing interests.

Ethics approval Not applicable.

Consent to participate Not applicable.

Consent for publication Not applicable.

Host factors in coronavirus replication

Ecology, evolution and classification of bat coronaviruses in the aftermath of SARS

SARS and MERS: recent insights into emerging coronaviruses

China Novel Coronavirus Investigating and Research Team (2020) A novel coronavirus from patients with pneumonia in China

Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses

A pneumonia outbreak associated with a new coronavirus of probable bat origin

First two months of the 2019 coronavirus disease (COVID-19) epidemic in China: real-time surveillance and evaluation with a second derivative model

COVID-19) -events as they happen. World Health Organization

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China

China Neurol Sci Medical Treatment Expert Group for Covid-19 (2020) Clinical characteristics of coronavirus disease 2019 in China

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease

Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2

Middle East respiratory syndrome coronavirus causes multiple organ damage and lethal disease in mice transgenic for human dipeptidyl peptidase 4

Evidence of the COVID-19 virus targeting the CNS: tissue distribution, hostvirus interaction, and proposed neurotropic mechanisms

Neuromuscular disorders in severe acute respiratory syndrome

Large artery ischaemic stroke in severe acute respiratory syndrome (SARS)

Olfactory neuropathy in severe acute respiratory syndrome: report of a case

Coronavirus infections in the central nervous system and respiratory tract show distinct features in hospitalized children

Human coronavirus OC43 associated with fatal encephalitis

Severe neurologic syndrome associated with Middle East respiratory syndrome corona virus (MERS-CoV)

Detection of coronavirus in the central nervous system of a child with acute disseminated encephalomyelitis

Neurological complications during treatment of Middle East Respiratory Syndrome

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses

The Ottawa Hospital Research Institute

CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials

Conducting meta-analyses in R with the metafor Package

Performance of statistical methods for meta-analysis when true study effects are nonnormally distributed: a comparison between DerSimonian-Laird and restricted maximum likelihood

Measuring inconsistency in meta-analyses

Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China

Acute cerebrovascular disease following COVID-19: a single center, retrospective, observational study. Stroke Vasc Neurol

New onset acute symptomatic seizure and risk factors in coronavirus disease 2019: a retrospective multicenter study

Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis

Humanitas COVID-19 Task Force (2020) Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in

Thrombotic and hemorrhagic events in critically ill COVID-19 patients: a French monocenter retrospective study

Hemorrhagic stroke and anticoagulation in COVID-19

Neurologic features in severe SARS-CoV-2 infection

High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study

Brain MRI findings in patients in the intensive care unit with COVID-19 infection

Italian SITIP-SIP Pediatric Infection Study Group, Italian SITIP-SIP SARS-CoV-2 paediatric infection study group* (2020) Multicentre Italian study of SARS-CoV-2 infection in children and adolescents, preliminary data as at 10

COVID-19 related neuroimaging findings: a signal of thromboembolic complications and a strong prognostic marker of poor patient outcome

Clinical characteristics and outcomes of inpatients with neurologic disease and COVID-19 in Brescia

New onset neurologic events in people with COVID-19 infection in three regions in China [published online ahead of print

Coronavirus 2019 (COVID-19)-associated encephalopathies and cerebrovascular disease: the New Orleans experience

Imaging in neurological disease of hospitalized COVID-19 patients: an Italian multicenter retrospective observational study

Brain imaging use and findings in COVID-19: a single academic center experience in the epicenter of disease in the United States

Neurologic manifestations in hospitalized patients with COVID-19: The ALBACOVID registry

Brain MRI findings in severe COVID-19: a retrospective observational study

Neurological manifestations and COVID-19: experiences from a tertiary care center at the frontline

Acute-onset smell and taste disorders in the context of COVID-19: a pilot multicentre polymerase chain reaction based case-control study

Self-reported olfactory and taste disorders in SARS-CoV-2 patients: a crosssectional study

Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study

Alterations in smell or taste in mildly symptomatic outpatients with SARS-CoV-2 infection

Objective evaluation of anosmia and ageusia in COVID-19 patients: single-center experience on 72 cases

Validation of a self-administered olfactory and gustatory test for the remotely evaluation of COVID-19 patients in home quarantine

Olfactory and gustatory function impairment in COVID-19 patients: Italian objective multicenter-study

Prevalence and duration of acute loss of smell or taste in COVID-19 patients

Olfactory dysfunction and sinonasal symptomatology in COVID-19: prevalence, severity, timing, and associated characteristics

Features of anosmia in COVID-19

Clinical features of patients infected with 2019 novel coronavirus in

Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study

Clinical features of 85 fatal cases of COVID-19 from Wuhan. A retrospective observational study

Epidemiological characteristics and clinical features of 32 critical and 67 noncritical cases of COVID-19 in Chengdu

Tracing new clinical manifestations in patients with COVID-19 in Chile and its potential relationship with the SARS-CoV-2 divergence

Clinical characteristics of 28 patients with diabetes and COVID-19 in Wuhan

Clinical features and treatment of COVID-19 patients in northeast Chongqing

Clinical features of 69 cases with coronavirus disease 2019 in Wuhan, China [published online ahead of print

Clinical features of severe pediatric patients with coronavirus disease 2019 in Wuhan: a single center's observational study

Characteristics of COVID-19 infection in Beijing

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

A case series describing the epidemiology and clinical characteristics of COVID-19 infection in Jilin Province

Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province

Strong associations and moderate predictive value of early symptoms for SARS-CoV-2 test positivity among healthcare workers, the Netherlands

Clinical characteristics and outcomes of patients with severe covid-19 with diabetes

Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series

Comparison of epidemiological and clinical characteristics of COVID-19 patients with and without Wuhan exposure

Clinical and epidemiologic profile of the initial COVID-19 patients at a tertiary care centre in India

Epidemiological, clinical characteristics of cases of SARS-CoV-2 infection with abnormal imaging findings

Epidemiological and clinical characteristics of 17 hospitalized patients with 2019 novel coronavirus infections outside Wuhan

Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial

Clinical and immune features of hospitalized pediatric patients with coronavirus disease 2019 (COVID-19) in Wuhan, China

Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: retrospective case series

Characteristics of patients with COVID-19 pneumonia at Hvidovre Hospital

Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study

Prevalence and clinical presentation of health care workers with symptoms of coronavirus disease 2019 in 2 Dutch hospitals during an early phase of the pandemic

Clinical characteristics and short-term outcomes of coronavirus disease 2019: retrospective, single-center experience of designated hospital in Poland

Coronavirus disease 2019 (COVID-2019) infection among health care workers and implications for prevention measures in a tertiary Hospital in Wuhan,China

Clinical characteristics of noncritically ill patients with novel coronavirus infection (COVID-19) in a Fangcang Hospital

Association between initial chest CT or clinical features and clinical course in patients with coronavirus disease 2019 pneumonia

Gong Z (2020) Clinical characteristics and drug therapies in patients with the common-type coronavirus disease 2019 in Hunan, China

Clinical features and outcomes of 98 patients hospitalized with SARS-CoV-2 infection in Daegu, South Korea: a brief descriptive study

Clinical findings of patients with coronavirus disease

Characteristics of disease progress in patients with coronavirus disease 2019 in Wuhan

Clinical course and outcome of 107 patients infected with the novel coronavirus, SARS-CoV-2, discharged from two hospitals in Wuhan, China

Clinical features, laboratory characteristics, and outcomes of patients hospitalized with coronavirus disease 2019 (COVID-19): early report from the United States

Clinical characteristics of patients with 2019 coronavirus disease in a non-Wuhan area of Hubei Province, China: a retrospective study

Sex-specific clinical characteristics and prognosis of coronavirus disease-19 infection in Wuhan, China: A retrospective study of 168 severe patients

Retrospective study of risk factors for severe SARS-Cov-2 infections in hospitalized adult patients

Clinical characteristics of a case series of children with coronavirus disease 2019

on behalf of the Korea National Committee for Clinical Management of COVID-19 (2020) Clinical course and outcomes of patients with severe acute respiratory syndrome coronavirus 2 infection: a preliminary report of the first 28 patients from the Korean cohort study on COVID-19

Covid-19 in critically ill patients in the Seattle region -case series

Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study

Clinical and immunological features of severe and moderate coronavirus disease 2019

Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19):a multi-center study in Wenzhou city

Clinical and computed tomographic imaging features of novel coronavirus pneumonia caused by SARS-CoV-2

Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2

Clinical and epidemiological characteristics of 1420 European patients with mild-to-moderate coronavirus disease 2019

Characteristics of health care personnel with COVID-19 -United States

Time course of anosmia and dysgeusia in patients with mild SARS-CoV-2 infection

Clinical features and short-term outcomes of 114 elderly patients with COVID-19 in Wuhan, China: a single-center, retrospective, observational study

Correlation analysis between disease severity and clinical and biochemical characteristics of 143 cases of COVID-19 in Wuhan, China: a descriptive study

Coronavirus disease-19 among children outside Wuhan

Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China

Clinical features and short-term outcomes of 221 patients with COVID-19 in Wuhan

Clinical features of 95 sequential hospitalised patients with novel coronavirus 2019 disease (COVID-19), the first UK cohort

Clinical and laboratory profiles of 75 hospitalized patients with novel coronavirus disease

Clinical characteristics of 36 non-survivors with COVID-19 in Wuhan, China. Infectious Diseases (except HIV/AIDS)

Association of chemosensory dysfunction and COVID-19 in patients presenting with influenza-like symptoms

Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 in Wuhan, China: a retrospective study

Clinical characteristics of 54 medical staff with COVID-19: a retrospective study in a single center in Wuhan

COVID-19: Symptoms, course of illness and use of clinical scoring systems for the first 42 patients admitted to a Norwegian local hospital

Clinical characteristics of Covid-19 in

Clinical features and short-term outcomes of 102 patients with coronavirus disease

Epidemiologic and clinical characteristics of novel coronavirus infections involving 13 patients outside Wuhan, China

Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records

Coronavirus disease 2019 in elderly patients: characteristics and prognostic factors based on 4-week follow-up

First cases of coronavirus disease 2019 (COVID-19) in the WHO European Region

Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury

Clinical features and dynamics of viral load in imported and non-imported patients with COVID-19

CT imaging features of 2019 novel coronavirus (2019-nCoV)

Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study

Epidemiological and clinical features of 200 hospitalized patients with corona virus disease 2019 outside Wuhan, China: a descriptive study

Relation between chest CT findings and clinical conditions of coronavirus disease (COVID-19) pneumonia: a multicenter study

A comparative-descriptive analysis of clinical characteristics in 2019-coronavirus-infected children and adults

Clinical course and outcomes of 344 intensive care patients with COVID-19

COVID-19 and anosmia in Tehran

COVID-19 anosmia reporting tool: initial findings

Coincidence of COVID-19 epidemic and olfactory dysfunction outbreak

Presentation of new onset anosmia during the COVID-19 pandemic

Stroke in patients with SARS-CoV-2 infection: case series

Large-vessel stroke as a presenting feature of Covid-19 in the young

Encephalopathy as the sentinel sign of a cortical stroke in a patient infected with coronavirus disease-19 (COVID-19). Cureus

Triage of acute ischemic stroke in confirmed COVID-19: large vessel occlusion associated with coronavirus infection

Letter to editor: severe brain haemorrhage and concomitant COVID-19 infection: a neurovascular complication of COVID-19

Status of SARS-CoV-2 in cerebrospinal fluid of patients with COVID-19 and stroke

Cerebral venous thrombosis: a typical presentation of COVID-19 in the young

Venous cerebral thrombosis in COVID-19 patient

Atypical deep cerebral vein thrombosis with hemorrhagic venous infarction in a patient positive for COVID-19

Cerebral venous thrombosis associated with COVID-19

First case of Covid-19 presented with cerebral venous thrombosis: a rare and dreaded case

Letter: thrombotic neurovascular disease in COVID-19 patients

Cerebral venous sinus thrombosis as a presentation of COVID-19

A case of coronavirus disease 2019 with concomitant acute cerebral infarction and deep vein thrombosis

Letter to editor: severe brain haemorrhage and concomitant COVID-19 infection: a neurovascular complication of COVID-19

COVID-19 and intracerebral haemorrhage: causative or coincidental? New Microbes New Infect 35:100669

COVID-19 neurologic complication with CNS vasculitis-like pattern

Macrothrombosis and stroke in patients with mild Covid-19 infection

Arterial and venous thromboembolic disease in a patient with COVID-19: a case report

Unusual simultaneous cerebral infarcts in multiple arterial territories in a COVID-19 patient

Piotin M Treatment of acute ischemic stroke due to large vessel occlusion with COVID-19: experience from Paris

Arterial thromboembolic complications in COVID-19 in low-risk patients despite prophylaxis

Characteristics of ischaemic stroke associated with COVID-19

An unresponsive COVID-19 patient

Thalamic perforating artery stroke on computed tomography perfusion in a patient with coronavirus disease 2019

Acute ischemic stroke complicating common carotid artery thrombosis during a severe COVID-19 infection

Coagulopathy and antiphospholipid antibodies in patients with Covid-19

Severe acute respiratory syndrome coronavirus 2 infection and ischemic stroke

Cerebrovascular disease in COVID-19

Ischemic stroke associated with novel coronavirus 2019: a report of three cases

A first case of meningitis/encephalitis associated with SARS-Coronavirus-2

SARS-CoV-2 detected in cerebrospinal fluid by PCR in a case of COVID-19 encephalitis

Soares CAS First case of SARS-COV-2 sequencing in cerebrospinal fluid of a patient with suspected demyelinating disease

Acute encephalopathy with elevated CSF inflammatory markers as the initial presentation of COVID-19

Neurological complications of coronavirus disease (COVID-19): encephalopathy. Cureus Published online

Neurological complications of coronavirus disease (COVID-19): encephalopathy, MRI brain and cerebrospinal fluid findings: case 2. Cureus

Newey CR Acute symptomatic seizures in critically ill patients with COVID-19: is there an association? Neurocrit Care Published online

Steroid-responsive encephalitis in coronavirus disease 2019

Concomitant neurological symptoms observed in a patient diagnosed with coronavirus disease 2019

Emamikhah M Evolution and resolution of brain involvement associated with SARS-CoV2 infection: a close clinical -paraclinical follow up study of a case

COVID-19-associated meningoencephalitis complicated with intracranial hemorrhage: a case report

Meningoencephalitis without respiratory failure in a young female patient with COVID-19 infection in Downtown Los Angeles

Lessons of the month 1: a case of rhombencephalitis as a rare complication of acute COVID-19 infection

SARS-CoV-2 can induce brain and spine demyelinating lesions

Focal status epilepticus as unique clinical feature of COVID-19: a case report

A case of COVID-19 infection presenting with a seizure following severe brain edema

COVID-19 presenting with seizures

COVID-19-related acute necrotizing encephalopathy with brain stem involvement in a patient with aplastic anemia

Frequent convulsive seizures in an adult patient with COVID-19: a case report

De novo status epilepticus in patients with COVID-19

Encephalitis associated with COVID-19 infection in an 11-yearold child

Neurologic manifestations in an infant with COVID-19

Transient cortical blindness in COVID-19 pneumonia; a PRES-like syndrome: case report

COVID-19-associated acute hemorrhagic necrotizing encephalopathy: CT and MRI features

COVID-19-associated delayed posthypoxic necrotizing leukoencephalopathy

COVID-19-associated mild encephalitis/encephalopathy with a reversible splenial lesion

COVID-19-associated acute disseminated encephalomyelitis (ADEM)

Acute dissemin ated encephalomyelitis after SARS-CoV-2 infection

Delirium in COVID-19: a case series and exploration of potential mechanisms for central nervous system involvement

COVID-19 in an elderly woman with acute functional decline. Covid-19 påvist hos eldre kvinne med akutt funksjonssvikt

Concomitant neurological symptoms observed in a patient diagnosed with coronavirus disease 2019

Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence?

COVID-19 may induce Guillain-Barré syndrome

Guillain-Barré syndrome as a complication of SARS-CoV-2 infection

Covid-19 and Guillain-Barré syndrome: more than a coincidence

SARS-CoV-2 and Guillain-Barré syndrome: AIDP variant with favorable outcome

Guillain-Barré syndrome related to SARS-CoV-2 infection

Guillain-Barré syndrome related to COVID-19 infection

Guillain-Barré syndrome following COVID-19: new infection, old complication?

Guillain-Barré syndrome in a patient with antibodies against SARS-COV-2

GUILLAIN-BARR é syndrome during SARS-COV-2 pandemic: a case report and review of recent literature

Guillain-Barré syndrome after SARS-CoV-2 infection

Guillain Barre syndrome associated with COVID-19 infection: a case report

Novel coronavirus (COVID-19)-associated Guillain-Barré syndrome: case report

New clinical manifestation of COVID-19 related Guillain-Barrè syndrome highly responsive to intravenous immunoglobulins: two Italian cases

Guillain-Barré syndrome associated with SARS-CoV-2 infection

Early Guillain-Barré syndrome in coronavirus disease 2019 (COVID-19): a case report from an Italian COVID-hospital

Facial diplegia, a possible atypical variant of Guillain-Barré syndrome as a rare neurological complication of SARS-CoV-2

Guillain-Barré syndrome following COVID-19: a newly emerging post-infectious complication

Post SARS-CoV-2 Guillain-Barré syndrome

Guillain-Barré syndrome associated with leptomeningeal enhancement following SARS-CoV-2 infection

Miller-Fisher syndrome after SARS-CoV-2 infection

Guillain-Barré syndrome associated with SARS-CoV-2

Miller Fisher syndrome and polyneuritis cranialis in COVID-19

COVID-19 presenting with ophthalmoparesis from cranial nerve palsy

COVID 19 infection presenting as motor peripheral neuropathy

A rare presentation of coronavirus disease 2019 (COVID-19) induced viral myositis with subsequent rhabdomyolysis

Rhabdomyolysis as potential late complication associated with COVID-19

Rhabdomyolysis as a presentation of 2019 novel coronavirus disease

Acute transverse myelitis after COVID-19 pneumonia

Generalized myoclonus in COVID-19

Cutaneous hyperesthesia: a novel manifestation of COVID-19

Oropharyngeal dysphagia and aspiration pneumonia following coronavirus disease 2019: a case report

Unique case of central retinal artery occlusion secondary to COVID-19 disease

Acute vision loss in a patient with COVID-19

Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus

Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis

Zika virus infection as a cause of congenital brain abnormalities and Guillain-Barré syndrome: systematic review

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

Susceptibility to SARS coronavirus S protein-driven infection correlates with expression of angiotensin converting enzyme 2 and infection can be blocked by soluble receptor

The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease

Neurological complications during treatment of Middle East respiratory syndrome

Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: a systematic review and meta-analysis

Clinicopathological characteristics of 8697 patients with COVID-19 in China: a meta-analysis

(2020) Clinical, laboratory and imaging features of COVID-19: a systematic review and meta-analysis

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations